Galmed Pharmaceuticals Ltd
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes me… Read more
Galmed Pharmaceuticals Ltd (GLMD) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.101x
Based on the latest financial reports, Galmed Pharmaceuticals Ltd (GLMD) has a cash flow conversion efficiency ratio of -0.101x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.94 Million) by net assets ($19.11 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Galmed Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Galmed Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Galmed Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Galmed Pharmaceuticals Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Digitree Group S.A
WAR:DTR
|
0.160x |
|
BC Moly Ltd.
V:BM
|
0.005x |
|
Taura Gold Inc
V:TORA
|
-0.153x |
|
SPDR Gold Shares
BE:GQ9
|
N/A |
|
AppTech Payments Corp. Warrant
NASDAQ:APCXW
|
-0.121x |
|
Visa Steel Limited
NSE:VISASTEEL
|
-0.005x |
|
Hochdorf Holding AG
SW:HOCN
|
-0.550x |
|
Goodyear Indonesia Tbk
JK:GDYR
|
0.057x |
Annual Cash Flow Conversion Efficiency for Galmed Pharmaceuticals Ltd (2012–2024)
The table below shows the annual cash flow conversion efficiency of Galmed Pharmaceuticals Ltd from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $16.33 Million | $-5.88 Million | -0.360x | +18.55% |
| 2023-12-31 | $13.88 Million | $-6.14 Million | -0.442x | +67.92% |
| 2022-12-31 | $13.42 Million | $-18.50 Million | -1.378x | -27.79% |
| 2021-12-31 | $30.50 Million | $-32.89 Million | -1.079x | -81.16% |
| 2020-12-31 | $44.15 Million | $-26.29 Million | -0.595x | -178.42% |
| 2019-12-31 | $69.85 Million | $-14.94 Million | -0.214x | -108.30% |
| 2018-12-31 | $87.89 Million | $-9.02 Million | -0.103x | +86.56% |
| 2017-12-31 | $15.79 Million | $-12.07 Million | -0.764x | +30.24% |
| 2016-12-31 | $11.07 Million | $-12.13 Million | -1.095x | -178.44% |
| 2015-12-31 | $21.55 Million | $-8.47 Million | -0.393x | -33.67% |
| 2014-12-31 | $31.41 Million | $-9.24 Million | -0.294x | -122.74% |
| 2013-12-31 | $-1.95 Million | $-2.52 Million | 1.294x | -16.85% |
| 2012-12-31 | $-1.98 Million | $-3.08 Million | 1.556x | -- |